SecBot SecBot
Insider Cluster (1 insider) ·Filed Mar 10, 2026

STOK

Stoke Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed8mo ago
Insider cluster: 3 insiders, $1.5M total
Actionable Insight • Neutral

Monitor for additional insider selling or commentary around clinical trial progress; current activity is routine and not materially concerning given the small size relative to market cap.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$38.35
T+0 close · Mar 9, 2026 · via day close
Latest settled
−23.18%
T+60 · $29.46
Vs SPY
−34.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $38.35entry
  2. T+1 · 8mo ago −1.07%α −0.96% · $37.94
  3. T+5 · 8mo ago −14.29%α −13.38% · $32.87
  4. T+20 · 7mo ago −9.07%α −8.92% · $34.87
  5. T+60 · 6mo ago −23.18%α −34.87% · $29.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A single insider sale occurred at Stoke Therapeutics, with Director Arthur A. Levin selling 605 shares for $22,264 in the past week. This transaction is part of a broader pattern of recent insider selling, with four sales totaling $1.8 million over the last 30 days. The activity represents minimal economic impact relative to the company's $1.9B market cap.

Key Financial Metrics

Direction
selling
Total Value
$22.3K
Insiders
1

Key Facts

  • Director Arthur A. Levin sold 605 shares at $36.80 per share for a total of $22,264
  • Transaction was an open-market sale (Form 4 code 'S')
  • Part of a cluster of 4 insider sales totaling $1.8M over the past 30 days
  • Total recent insider selling ($1.8M) represents only 0.09% of the company's $1.9B market cap

Financial Impact

$22,264 in open-market sales by one director; $1.8M total insider sales over 30 days

insider ownershipmarket sentiment

Risk Factors

  • Continued insider selling could signal waning confidence
  • Biotech valuation sensitivity to clinical trial outcomes not reflected in this filing

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (1 trades, 7d window)cluster-STOK-1773782609580

Track record

18 reports on STOK

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
  6. Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
  7. Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
  8. Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
  9. Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
  10. Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026